InMed Pharmaceuticals Inc. entered into Amendment No. 1 to its merger agreement with Mentari Therapeutics, Inc. to clarify transaction sequencing, including a name change to Mentari Therapeutics, Inc. and redomestication to Nevada. The amendment introduces a Company PIPE Amendment to facilitate potential pre-closing private placement financing and clarifies tax treatment as an integrated reorganization. InMed Pharmaceuticals Inc. is a biopharmaceutical company focused on developing medicinal plant-derived cannabinoid-based therapeutics.
